##  [Product sales](/investors/financial-data/product-sales "Product sales") 

 ## Full year 2025 product sales

The following table provides the top 20 product net sales from continuing operations in 2025, as well as the change compared with 2024:

**Brands**  
 **Net Sales**  
**(USD m)****% change**  
**(USD)****% change**  
**(cc1)****Brand classification by therapeutic area or established brands***Entresto*7,748-1-2Cardiovascular, renal and metabolic*Cosentyx*6,66898Immunology*Kisqali*4,7835857Oncology*Kesimpta*4,4263736Neuroscience*Tafinlar + Mekinist*2,21586Oncology*Jakavi*2,11097Oncology*Pluvicto*1,9944342Oncology*Ilaris*1,8832524Immunology*Xolair2*1,72354Immunology*Promacta/Revolade*1,636-26-27Oncology*Scemblix*1,2858785Oncology*Zolgensma* Group1,23210Neuroscience*Sandostatin* Group1,213-5-5Established brands*Leqvio*1,1985957Cardiovascular, renal and metabolic*Tasigna*1,104-34-34Oncology*Lutathera*8161312Oncology*Exforge* Group72734Established brands*Lucentis*643-38-40Established brands*Diovan* Group60422Established brands*Fabhalta*3505291287Oncology

 



 

 

 

 

1. For an explanation of non-IFRS measures and reconciliation tables, see the Annual Report 2025: “—Non-IFRS measures as defined by Novartis.”
2. Net sales from continuing operations reflect *Xolair* sales for all indications.
3. Net sales from continuing operations reflect *Fabhalta* sales for all indications.